Skip to main content
Vistin Pharma logo

Vistin Pharma — Investor Relations & Filings

Ticker · VISTN ISIN · NO0010734122 LEI · 5967007LIEEXZXFQY092 OL Manufacturing
Open in API
Filings indexed 519 across all filing types
Latest filing 2023-04-28 Remuneration Information
Country NO Norway
Listing OL VISTN

About Vistin Pharma

https://www.vistin.com/

Vistin Pharma is a pharmaceutical company specializing in the production of Metformin Hydrochloride, an Active Pharmaceutical Ingredient (API). The company operates as a pure-play, global supplier, providing high-quality Metformin to pharmaceutical companies worldwide. In addition to the standard API, Vistin Pharma offers specialized grades such as Direct Compressible (DC) Metformin. With over 50 years of experience, the company emphasizes sustainable manufacturing from its dedicated European production facility.

Recent filings

Filing Released Lang Actions
Notice of Annual General Meeting in Vistin Pharma ASA
Remuneration Information Classification · 98% confidence The document is explicitly titled "Statement regarding the determination of salary and other remuneration to Executive Management" and details the principles, regulatory landscape, decision-making process, and composition of remuneration for both the Board of Directors and the Executive Management Team. It discusses fixed salaries, bonuses (STIP), pension plans, and Long Term Incentive Plans (LTIP). This content directly aligns with the definition of a report detailing compensation for top executives and directors. The classification code for this type of document is DEF 14A (Remuneration Information), even though the document itself is a policy statement that will be submitted for approval at the AGM, the core subject matter is remuneration disclosure.
2023-04-28 English
Notice of Annual General Meeting in Vistin Pharma ASA
Remuneration Information Classification · 100% confidence The document is explicitly titled "Remuneration report for salary and other remuneration for leading persons 2022". It contains detailed sections on the remuneration of the Board of Directors and Executive Management, including fixed salaries, bonuses (STIP), pension plans, and long-term incentive plans (LTIP) for the fiscal year 2022, comparing figures to 2021. This content directly aligns with the definition of a Remuneration Information report, which corresponds to the DEF 14A code in the provided schema, even though the document itself is not explicitly labeled as a DEF 14A filing. Given the specific focus on executive and board compensation, DEF 14A is the most appropriate classification.
2023-04-28 English
Notice of Annual General Meeting in Vistin Pharma ASA
AGM Information Classification · 100% confidence The document text explicitly contains the phrases "INNKALLING TIL ORDINÆR GENERAL FORSAMLING I VISTIN PHARMA ASA" (Calling Notice for Annual General Meeting in Vistin Pharma ASA) and "CALLING NOTICE FOR ANNUAL GENERAL MEETING IN VISTIN PHARMA ASA". This clearly indicates the document is a notice or material related to the Annual General Meeting (AGM). According to the definitions, AGM-R covers "Presentations and materials shared during the Annual General Meeting (AGM)". Since this is the official calling notice for the AGM, AGM-R is the most appropriate classification.
2023-04-28 Norwegian
Notice of Annual General Meeting in Vistin Pharma ASA
AGM Information Classification · 98% confidence The document explicitly mentions 'Proposal from the Election Committee in Vistin Pharma ASA for the Annual General Meeting to be held in May 2023'. It details proposals regarding the election of Board members, the re-election of the Election Committee, and adjustments to remunerations for these committees and the Board, all tied to the upcoming AGM. This content strongly aligns with the materials presented or discussed during an Annual General Meeting, making 'AGM Information' (AGM-R) the most appropriate classification. It is not a full 10-K, an earnings release, or a proxy statement (DEF 14A/PSI), but rather the specific proposals being put forward for shareholder vote at the AGM.
2023-04-28 English
Notice of Annual General Meeting in Vistin Pharma ASA
Annual Report (ESEF) Classification · 100% confidence FY 2022
2023-04-28 Norwegian
Notice of Annual General Meeting in Vistin Pharma ASA
Annual Report Classification · 100% confidence The document is titled 'Directors' report for 2022' and contains comprehensive financial results, management discussion and analysis (MDA), sustainability/ESG reporting, and board information for the full fiscal year 2022. It includes detailed financial statements, cash flow analysis, and balance sheet data. As it covers the full fiscal year and provides a comprehensive overview of the company's performance, it is classified as an Annual Report (10-K equivalent for non-US entities). FY 2022
2023-04-28 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.